Cannabidiol-Induced Recovery of Social Behaviour in Mouse Models of Syndromic Autism
Abstract
Despite
the
growing
prevalence
of
autism,
no
pharmacological
interventions
have
been
approved
for
core
symptoms.
The
endocannabinoid
system
(ECS)
has
recently
gained
interest
as
a
potential
target
treating
autism.
Cannabidiol
(CBD),
compound
found
in
Cannabis
plant
(C.
Sativa ),
is
autism
treatment
due
to
its
tolerability
and
promising
early
results
fragile
X
syndrome
patients.
Here,
we
aimed
evaluate
efficacy
CBD
social
deficits
restrictive/repetitive
behaviours
two
monogenetic
models
Shank3
Fmr1
knock-out
(KO)
mice.
Male
female
mice
were
tested
3-chamber
apparatus
or
self-grooming
open
field
test
(baseline
pre-treatment),
followed
by
five
daily
treatments
vehicle
(s.c.,
5mg/kg
males
50mg/kg
females)
again
after
last
injection
(post-treatment).
At
baseline
following
treatment,
male
KO
exhibited
novelty,
which
restored
control
levels
administration.
Meanwhile,
(increased
mice)
open-field
exploration
(decreased
locomotion
not
affected
CBD.
Females
had
hippocampal
~
11.6
times
higher
than
(concordant
with
dosing)
presented
elevated
anandamide
(AEA)
CBD-treated
groups.
Transcriptomic
analysis
hippocampus
revealed
lack
overlap
differentially
expressed
genes
(DEGs)
among
different
strains
between
sexes.
These
suggest
sex-
strain-specific
mechanisms
support
therapeutic
effects
syndromic
Research Square (Research Square), Год журнала: 2025, Номер unknown
Опубликована: Май 22, 2025
Язык: Английский